A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy. Subscribe ...

Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Evry, January 23, 2025- Genethon, a pioneer and leader in the research and development of gene therapies for rare diseases, and Eukarÿs, a biotechnology company developing a disruptive technology that ...

VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology ...

Adenoviral vectors have emerged as a pivotal platform in gene therapy owing to their efficient gene delivery and high transgene expression. Their application spans from vaccine development to ...

Viral vectors are critical vehicles for the delivery of life-saving cell and gene therapies. Adeno-associated virus (AAV) and lentiviral vectors (LVV), two of the most widely used vector platforms, ...

The re-transcribed DNA is then integrated into the genome of the host cell (Figure 2). This process requires the absence of the nuclear membrane and thus is restricted to the M-phase of proliferating ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced ...